Aarti Pharmalabs Ltd (AARTIPHARM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Aarti Pharmalabs Ltd on NSE and BSE, with an AI summary of each filing.
Audio Recording of Conference Call for Investor and Analysts
Audio / Video · 30 Oct 2026, 12:12 am
Aarti Pharmalabs Releases Audio Recording of Q2 FY27 Earnings Conference Call Aarti Pharmalabs Limited announced on 29th Oct'26 that the audio recording for its investors and analysts earnings conference call regarding the unaudited financial results for Q2 ended 30th Sep'26 has been uploaded to its official website. The disclosure complies with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, following the company’s prior intimation dated 22nd Oct'26. Stakeholders can access the recording directly via the designated investor relations webpage.
Q2 FY 2027 Investor Presentation
Investor Presentation · 29 Oct 2026, 7:00 pm
Aarti Pharmalabs Reports Strong Q2 FY27 Operating Performance and Expansion Plans Aarti Pharmalabs delivered strong Q2 FY27 consolidated operational revenue of INR 6,105 Mn (up 45.9% YoY, 13.9% QoQ), with EBITDA surging 80.2% YoY to INR 1,346 Mn and PAT rising 248.8% YoY to INR 715 Mn. Xanthine Derivatives contributed 50% of revenue, followed by API/Intermediates at 30% and CDMO/CMO at 13%. The firm is investing INR 149 Cr in Atali Block 2 (~405 KL) for CDMO, targeting commercialization by H2 FY28, while guiding for a 15–18% revenue and EBITDA CAGR over 3–4 years.
Please find enclosed
Others (Uncategorized) · 29 Oct 2026, 3:28 am
Aarti Pharmalabs Reports Strong Q2 FY27 Results and Appoints New CFO Aarti Pharmalabs reported consolidated revenue from operations of ₹61,045.10 lakhs for Q2 ended 30th Sep'26, up 45.9% YoY from ₹41,833.48 lakhs, while net profit jumped 248.8% YoY to ₹7,147.23 lakhs. Sequentially, revenue grew 13.9% QoQ from ₹53,579.69 lakhs, but net profit declined 6.1% QoQ. Diluted EPS stood at ₹7.87. Additionally, the company appointed Smt. Vibha Thakkar as CFO effective 31st Oct'26, following the resignation of Shri Piyush Lakhani effective 30th Oct'26. The board also recognized an exceptional demerger stamp duty provision of ₹204.00 lakhs.
Please find enclosed
Change in Management · 29 Oct 2026, 2:36 am
Aarti Pharmalabs Reports Strong Q2 Results and Appoints New CFO Aarti Pharmalabs posted a 45.9% YoY surge in Q2 consolidated revenue from operations to Rs 61,045.10 lakhs, with net profit rising 248.8% YoY to Rs 7,147.23 lakhs. For H1 ended 30th Sep'26, consolidated revenue grew 42.5% YoY to Rs 1,14,624.79 lakhs and net profit jumped 121.8% YoY to Rs 14,761.49 lakhs. The board accepted the resignation of CFO Piyush Lakhani, effective 30th Oct'26, and appointed Vibha Thakkar as CFO effective 31st Oct'26. Additionally, the company recognized an exceptional provision of Rs 204.00 lakhs regarding stamp duty disputes.
Please find enclosed
Change in Management · 29 Oct 2026, 2:34 am
Aarti Pharmalabs Reports Strong Q2 FY27 Results and Appoints New CFO Aarti Pharmalabs reported consolidated Q2 revenue from operations of Rs 61,045.10 lakhs for the quarter ended 30th Sep'26, up 45.9% YoY from Rs 41,833.48 lakhs. Consolidated net profit surged 248.8% YoY to Rs 7,147.23 lakhs compared to Rs 2,049.27 lakhs in Q2 FY26. Diluted EPS rose to Rs 7.87 from Rs 2.26. The board recognized an exceptional provision of Rs 204.00 lakhs regarding a disputed Gujarat stamp duty order. Additionally, Smt. Vibha Thakkar was appointed CFO, effective 31st Oct'26, succeeding Shri Piyush Lakhani.
Aarti Pharmalabs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 29 Oct 2026, 2:32 am
Please find enclosed
Financial Result · 29 Oct 2026, 2:29 am
Please find enclosed
Outcome · 29 Oct 2026, 2:25 am
Aarti Pharmalabs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakh) ■ Revenue: 61,045 (+45.9% YoY | +13.9% QoQ) ■ EBITDA: 13,516 (+110.0% YoY | -0.7% QoQ) ■ EBITDA Margin (%): 22.1 (+676 bps YoY | -326 bps QoQ) ■ PAT: 7,147 (+248.8% YoY | -6.1% QoQ) ■ EPS (INR): 7.87 (+248.2% YoY | -6.2% QoQ)
Please find enclosed
Others (Uncategorized) · 29 Oct 2026, 1:49 am
Aarti Pharmalabs Revamps Corporate Website to Enhance Navigation and Accessibility Aarti Pharmalabs Limited announced on 28th Oct'26 that it has revamped its official website pursuant to Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The overhaul is aimed at improving design, user navigation, and overall digital accessibility. The updated platform remains accessible to investors and stakeholders at the company's existing web address, www.aartipharmalabs.com.
Please find enclosed
Others (Uncategorized) · 29 Oct 2026, 1:23 am
Aarti Pharmalabs Approves Grant of 850 Stock Options Under PSOP 2023 Aarti Pharmalabs Limited's Nomination and Remuneration Committee approved the grant of 850 stock options to eligible employees under the APL Performance Stock Option Plan 2023 (PSOP 2023) at its meeting on 28th Oct'26. The options are granted at an exercise price of Rs. 5 per option, compliant with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.
This is to inform you that the Earnings Conference Call for investors and analysts has been scheduled for Thursday, October 28, 2026, at 3:30 p.m. (IST) to discuss the Company''s Q2-FY27 ....
Intimation · 29 Oct 2026, 3:30 pm
Aarti Pharmalabs Schedules Q2 & H1 FY27 Earnings Call on 29th Oct'26 Aarti Pharmalabs Limited will host its earnings conference call on 29th Oct'26 at 3:30 PM IST to discuss the operational and financial performance for Q2 & H1 FY27. Key management participants include Managing Director Rashesh Gogri, Chief Financial Officer Piyush Lakhani, and Executive Director Hetal Gogri Gala. The call is hosted by PhillipCapital (India) Private Limited. Primary dial-in access numbers are +91 22 6280 1143 and +91 22 7115 8044.
Aarti Pharmalabs Ltd has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 28 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 28 Oct 2026, 5:30 am
Aarti Pharmalabs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve Unaudited Standalone And Consolidated ....
Intimation · 28 Oct 2026, 5:30 am
Aarti Pharmalabs Board Meeting Scheduled for 28th Oct'26 to Consider Q2 Results Aarti Pharmalabs Limited has scheduled its Board of Directors meeting for 28th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30th Sep'26, along with the Limited Review Reports. In compliance with insider trading regulations, the company's trading window for securities transactions, closed since 1st Oct'26, will remain shut until 30th Oct'26 following the earnings announcement.
Please find enclosed
Others (Uncategorized) · 30 Sept 2026, 11:08 pm
Aarti Pharmalabs Challenges Rs 59.50 Crore Stamp Duty Demand in Gujarat HC Aarti Pharmalabs has filed a Writ Petition before the Hon'ble High Court of Gujarat challenging an order dated 29th Aug'26 issued by the Superintendent of Stamps, Gandhinagar. The contested order levied stamp duty and penalties totaling Rs 59.50 crore concerning its NCLT-sanctioned Scheme of Arrangement (Demerger) dated 21st Sep'22.
Please find enclosed
Others (Uncategorized) · 30 Sept 2026, 4:30 pm
Aarti Pharmalabs Approves Reconstitution of Nomination and Remuneration Committee Aarti Pharmalabs Limited announced that its Board of Directors approved the reconstitution of its Nomination and Remuneration Committee on 30th Sep'26, effective from 1st Oct'26. The restructured four-member committee is chaired by Independent Director Smt. Jeenal Savla. Other members include Independent Directors Dr. Vinay Nayak and Shri Pradeep Thakur, alongside Executive Director Shri Rashesh Gogri.
Please find enclosed
Others (Uncategorized) · 24 Sept 2026, 12:20 am
Aarti Pharmalabs Approves Key Board and Leadership Reshuffle at AGM Aarti Pharmalabs shareholders approved key directorate changes at the 7th AGM on 22nd Sep'26. Non-Executive Director Rajendra Gogri ceased to be on the Board from 22nd Sep'26 after not offering himself for re-appointment upon retirement by rotation. Effective 1st Oct'26, Rashesh C. Gogri has been appointed as Managing Director, transitioning from his earlier role as Non-Executive Director. Simultaneously, Hetal Gogri Gala has been re-designated from Managing Director to Whole-time Director, also effective 1st Oct'26.
Scrutinizers Report and Voting Result of 7th Annual General Meeting
Annual General Meeting · 23 Sept 2026, 11:53 pm
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gloire Trusteeship Services Pvt Ltd & Others
Acquisition/ Disposal of Shares · 23 Sept 2026, 4:47 pm
Promoter Group Trims Stake in Aarti Pharmalabs to 39.66% The promoter and promoter group of Aarti Pharmalabs Limited reduced their aggregate holding by 3.20% (net 29,02,975 shares) via open/off-market transactions between 19th Sep'25 and 21st Sep'26. Gloire Trusteeship Services Pvt. Ltd. (Lotus Family Trust) fully exited its 0.69% stake (6,24,500 shares), while other promoters saw gross sales of 24,78,539 shares (2.73%) and acquisitions of 2,00,064 shares (0.22%). Consequently, total promoter group ownership declined from 42.88% (3,88,67,400 shares) to 39.66% (3,59,64,425 shares), against an expanded total equity base of 9,06,79,813 shares.
Investor Presentation made at the 7th Annual General Meeting
Investor Presentation · 22 Sept 2026, 11:49 pm
Proceedings of the 7th Annual General Meeting
Annual General Meeting · 22 Sept 2026, 10:56 pm
Please find enclosed
Others (Uncategorized) · 03 Sept 2026, 1:59 am
Aarti Pharmalabs Faces Rs 59.50 Crore Stamp Duty Demand Regarding Demerger Aarti Pharmalabs received an order on 1st Sep'26 from Gujarat stamp authorities levying Rs 59.50 crore in stamp duty and penalties. The 29th Aug'26 order alleges a short payment of stamp duty concerning the 21st Sep'22 NCLT-approved demerger of Aarti Industries' pharma division into Aarti Pharmalabs. The total liability includes Rs 25 crore in base stamp duty and Rs 34.50 crore in associated penalties. Management believes it has strong merits to contest the claims and will initiate appropriate legal actions to challenge the order.
Please find enclosed
Change in Management · 01 Sept 2026, 1:14 am
Aarti Pharmalabs Announces Senior Management Resignation Aarti Pharmalabs announced the resignation of Shri G.M. Naidu, Manufacturing/Sr. General Manager, citing personal commitments. He tendered his resignation via email on Jun 10, '26, and his official relieving date is Aug 31, '26. The company has filed this as a cessation of Senior Management Personnel under SEBI regulations. This marks a change in the company's operational leadership team.
Please find enclosed BRSR for FY 2025-26
Others (Uncategorized) · 29 Aug 2026, 8:54 pm
Aarti Pharmalabs: FY26 Business Responsibility and Sustainability Report Highlights Aarti Pharmalabs' FY26 BRSR details a strong focus on exports, which accounted for 55.93% of total turnover, serving 51 international markets. The business is segmented into APIs, Pharmaceutical Intermediates, & NCEs (51% of turnover) and Xanthine Derivatives (49%). Employee turnover for permanent staff was 23.45%. Accounts payable days improved to 92 from 103 in FY25. The company received a CGST penalty order for a demand of ₹31,15,608 due to alleged excess input tax credit availed in prior years; no appeal has been preferred.
Please find enclosed
Annual General Meeting · 29 Aug 2026, 8:47 pm